UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2024 » Volume 32, issue 3 (120) » PULSE THERAPY WITH CORTICOSTEROIDS IN PATIENTS WITH MULTIPLE SCLEROSIS: ADVERSE EVENTS AND WAYS TO OVERCOME THEM

PULSE THERAPY WITH CORTICOSTEROIDS IN PATIENTS WITH MULTIPLE SCLEROSIS: ADVERSE EVENTS AND WAYS TO OVERCOME THEM

Authors

Type of Article

  • Scientific Article

In the Section

  • MECHANISMS OF FORMATION AND MODERN PRINCIPLES OF TREATMENT OF NEUROLOGICAL DISORDERS

Key words

Index UDK:
  • 616.832-004.12:616.8-085.2/.3

Abstract

  • Pulse therapy with methylprednisolone remains the standard treatment for exacerbations of multiple sclerosis (MS). The appointment of glucocorticoids can cause a number of undesirable phenomena and complications, one of which is the development of steroid myopathy and pronounced general weakness. As a way to reduce the expressiveness of these violations, «Metacartin» was used. The study included 57 patients with a reliable diagnosis of multiple sclerosis at the stage of exacerbation of the pathological process. There were 32 (56.14 %) patients with the relapsing-remitting course (RRC) of MS, and 25 (43.86 %) with the secondaryprogressive course (SPC). All patients were randomly divided into two groups: I — 33 (57.89 %) patients who underwent a course of pulse therapy with methylprednisolone followed by the introduction of «Metacartin», and II — 24 (42.11 %) patients who received only pulse therapy methylprednisolone therapy. Group I included 23 patients with RRP and 10 patients with SPC MS. 15 patients with RRC and 9 patients with SPC MS were included in the II group. The study showed the effectiveness of combination of pulse-therapy with methylprednisolone and the drug "Metacartin", the prescription of which reliably reduced the severity of "muscular" symptoms when pulse therapy was prescribed.

Pages

  • 18-25

Year / Issue

Download PDF

Bibliography

1. Voloshina N. P., Negreba T. V., Vasilovskiy V. V., Pesotskaya K. O., Chernenko M. E. Sravnitelnaya effektivnost gormonalnoy puls-terapii pri retsidiviruyushchem i vtorichno-progrediyentnom tipakh techeniya rasseyannogo skleroza s raznym kharakterom prognoza (Soobshcheniye II. Effektivnost gormonalnoy puls-terapii v debyutakh i na retsidiviruyushchem etape pri retsidiviruyushchem i vtorichno-progrediyentnom tipakh techeniya rasseyannogo skleroza s raznym kharakterom prognoza) [Comparative effectiveness of hormonal pulse therapy in relapsing and secondary progressive types of multiple sclerosis with different types of prognosis (Message II. Efficacy of hormonal pulse therapy in the onset and at the relapsing stage in relapsing and secondary progressive types of multiple sclerosis with different types of prognosis)]. Mіzhnarodniy nevrologіchniy zhurnal [International Neurological Journal]. 2018. № 7 (101). S. 11—16. DOI: 10.22141/2224-0713.7.101.2018.149659. (In Russian).
2. Disability outcomes of early cerebellar and brainstemsymptoms in multiple sclerosis / Le M., Malpas C., Sharmin S.[et al.] // Multiple Sclerosis Journal. 2021. Vol. 27 (5). P. 755—766.DOI: 10.1177/1352458520926955.
3. Multiple sclerosis / Thompson A. J., Baranzini S. E., Geurts J.[et al.] // Lancet. 2018. Vol. 391, Is. 10130, P. 1622—1636. DOI:10.1016/S0140-6736(18)30481-1.
4. Voloshina N. P., Egorkina O. V. Strategii lecheniya rasseyannogo skleroza: effektivnost' i bezopasnost' [Treatment strategies for multiple sclerosis: efficacy and safety]. Ukrainskyi medychnyi chasopys [Ukrainian medical journal]. 2012. No. 4 (90). P. 32—37. (In Russian).
5. Voloshina N. P., Vasilovskiy V. V., Mikulinskiy Yu. E., Shchegel'skaya E. A. Autoterapiya kletkami stromy kostnogo mozga, indutsirovannymi v nervnyye, bol'nykh s khronicheskimi zadolevaniyami TSNS (rasseyannyy skleroz, bolezn' Parkinsona) [Autotherapy with bone marrow stromal cells induced into nerve cells of patients with chronic CNS diseases (multiple sclerosis, Parkinson's disease)]. Ukrainian Neurosurgical Journal. 2003. P. 61—66. (In Russian).
6. Karussis D. Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES /Karussis D., Kassis I., Petrou P. // Multiple Sclerosis Journal. 2022.Vol. 28, issue 9. P. 1324—1326. DOI: 10.1177/13524585211062173
7. Voloshin P. V., Vorob'yeva T. M., Voloshina N. P. Neyrobiologicheskiye mekhanizmy terapevticheskikh effektov distantnoy transplantatsii embrional'nykh nervnykh tkaney pri modelirovanii rasseyannogo skleroza [Neurobiological mechanisms of therapeutic effects of distant transplantation of embryonic nerve tissues in modeling multiple sclerosis]. Ukrainskyi visnyk psykhonevrolohii [Ukrainian Bulletin of Psychoneurology]. 2005. Vol. 13, iss. 1 (42). P. 5—9. (In Russian).
8. T-cell apoptosis in  situ in  experimental autoimmuneencephalomyelitis following methylprednisolone pulse therapy  / J. Schmidt, R. Gold, L. Schonroch [et al.] // Brain. 2000.Vol. 123 (Pt 7). P. 1431—1441. DOI: 10.1093/brain/123.7.1431.
9. Chernenko M. E. Albumin kak pokazatel pronitsayemosti gematoentsefalicheskogo baryera u bolnykh rasseyannym sklerozom [Albumin as an indicator of blood-brain barrier permeability in patients with multiple sclerosis]. Mezhdunarodnyy meditsinskiy zhurnal [International Medical Journal]. 2013. Vol. 19. No. 2 (74). P. 17—20. (In Russian).
10. Chernenko M. E. Matriksnaya metalloproteinaza-9 kak pokazatel aktivnosti vospalitelnogo protsessa u bolnykh rasseyannym sklerozom [Matrix metalloproteinase-9 as an indicator of the activity of the inflammatory process in patients with multiple sclerosis]. Tavricheskiy zhurnal psikhiatrii [Tavrichesky Journal of Psychiatry]. 2012. Vol. 16. No. 4 (61). P. 96—100. (In Russian).
11. The effect of oral and intravenosus methylprednisolonetreatment on subsequent relapse rate in multiple sclerosis /B. Sharrack, R. C. Hughes, R. W. Morris [et al.] // J. Neurol. Sci.2000. No. 17. P. 73-—77. DOI: 10.1016/s0022-510x(99)00304-4.
12. Nehrych T. I., Sorokin B. V., Yevtushenko S. K. Vid virohidnoi diahnostyky do efektyvnoi terapii rozsiianoho sklerozu. [From probable diagnosis to effective therapy of multiple sclerosis]. Mizhnarodnyi nevrolohichnyi zhurnal [International Journal of Neurology]. 2012. No. 3. P. 152—158. (In Ukrainian).
13. The effects of high-dose intravenous methylprednisolone on  event-related potentials in  patients with multiplesclerosis / [Filipovic S. R., Drulovic J., Stojsavljevic N., Levic Z.] //J. Neurol Sci. 1997. Vol. 152 (2):147—153. DOI: 10.1016/S0022-510X(97)00159-7.
14. Gold R. Mechanism of  action of  glucocorticosteroidhormones: possible implications for therapy of neuroimmunological disorders / R. Gold, F. Buttgereit, K. V. Toyka //J. Neuroimmunol. 2001. Vol. 117(1-2). P. 1—8. DOI: 10.1016/S0165-5728(01)00330-7.
15. Schäcke H. Mechanisms involved in  the side effectsof glucocorticoids / H. Schäcke, W. D. Döcke, K. Asadullah //Pharmacol Ther. 2002. Vol. 96 (1). P. 23—43. DOI: 10.1016/s0163-7258(02)00297-8.
16. Dose-related patterns of glucocorticoid-induced side effects / Huscher D., Thiele K., Gromnica-Ihle E. [et al.] // Ann RheumDis. 2009. Vol. 68 (7) P. 1119—24. DOI: 10.1136/ard.2008.092163.
17. Voloshina N. P. , Vasilovskiy V. V., Chernenko M. E. Vliyaniye infektsionnogo faktora na sostoyaniye gematoentsefalicheskogo baryera u bolnykh rasseyannym sklerozom [The influence of the infectious factor on the state of the blood-brain barrier in patients with multiple sclerosis]. Ukrainskyi visnyk psykhonevrolohii [Ukrainian Bulletin of Psychoneurology]. 2013. Vol. 21, iss. 1 (74). P. 5—7. (In Russian).
18. Glucose tolerance, insulin sensitivity and β-cell functionin patients with rheumatoid arthritis treated with or withoutlow-to-medium dose glucocorticoids / Hoes J. N., van derGoes M. C., van Raalte D. H. [et al.] // Ann Rheum Dis. 2011.Vol. 70 (11). P. 1887—94. DOI: 10.1136/ard.2011.151464.
19. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs / [Piper J. M., Ray W. A., Daugherty J. R., Griffin M. R.] // Ann Intern Med. 1991. Vol. 114 (9).P. 735—740. DOI: 10.7326/0003-4819-114-9-735.
20. Brown E. S. Mood and Cognitive Changes During Systemic Corticosteroid Therapy / E. S. Brown, P. A. Chandler //Prim Care Companion J Clin Psychiatry. 2001. Vol. 3 (1):17—21.DOI: 10.4088/pcc.v03n0104.
21. Stuart F. A. Adverse psychological effects of corticosteroids in children and adolescents / F. A. Stuart, T. Y. Segal,S. V. Keady // Arch. Dis. Child. 2005. Vol. 90(5). P. 500—506.DOI: 10.1136/adc.2003.041541.
22. Long-term exposure to medium-dose glucocorticoidtherapy associates with hypertension in patients with rheumatoid arthritis / Panoulas V. F., Douglas K. M., StavropoulosKalinoglou A. [et al.] // Rheumatology (Oxford). 2008. Vol. 47 (1).P. 72—75. DOI: 10.1093/rheumatology/kem311.
23. Whitworth J. A. Mechanisms of glucocorticoid-inducedhypertension  // Kidney Int.  1987. Vol.  31(5). P.  1213—1224.DOI: 10.1038/ki.1987.131.
24. Goodman and Gilman’s: The  Pharmacological Basisof Therapeutics / by Joel G. Hardman., Lee E. Limbird., AlfredGoodman Gilman. 9th edition. New York, 1996. 1905 p.
25. Chernenko M. Ye. Problema neirohenezu v umovakh terapii neirozapalnoho/neirodeheneratyvnoho protsesu [The problem of neurogenesis in the conditions of therapy of the neuroinflammatory/neurodegenerative process]. Mizhnarodnyi medychnyi zhurnal [International Medical Journal]. 2019. Vol. 25, No. 2 (98). P. 53—56. (In Ukrainian). URI: http://dspace.nbuv.gov.ua/handle/123456789/161027.
26. Dalakas M. C. Current treatment of the inflammatorymyopathies // Curr Opin Rheumatol. 1994. Vol. 6. P. 595—601.DOI: 10.1097/00002281-199411000-00008.
27. Changes of the MS Functional Composite and EDSS during and after treatment of relapses with methylprednisolonein patients with multiple sclerosis / Patzold T., Schwengelbeck M.,Ossege L. M. [et al.] // Acta Neurol Scand. 2002. Vol. 105 (3).P. 164—168. DOI: 10.1034/j.1600-0404.2002.1o135.x.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»